Stocktwits on MSN4h
News Movers: Your Daily Digest of Stocks That Released News Which Moved the MarketSpace (Trump's Space Force), AI (The Theme of the Year) WealthyVC.com scans North America’s 10,000+ publicly listed stocks ...
Cassava Sciences' Alzheimer's drug trials disappointed, leading to early study discontinuations. Check out why I rate SAVA ...
NEW YORK, NY / ACCESSWIRE / December 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...
Research analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Cassava Sciences in a research report issued on Tuesday, November 26th. HC Wainwright analyst V. Bernardino ...
NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...
Cassava Sciences Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of 0.00% with a gross margin of -82.27%. The profit margin, also known as the ...
On Tuesday, Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $3.83 which represents a decrease of $-0.47 or -10.93% from the prior close of $4.3. The stock opened at $4.32 and ...
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...
Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...
That was the case this morning with once high-flying stock Cassava Sciences (SAVA). This is a stock that once skyrocketed to $146. A little over three years later, this thing closed the day at $4.30, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback